MAT / RESEARCH / SPECIMENSPEC v3.2 · SPECIMEN
01 / STATEMENT
Matilon Research · Schema v3.2 · Record Specimen
Record Specimen
The following document is a complete specimen of a Matilon Research issuance, rendered across all three issued representations. Issuances distributed to authorized recipients adhere to this format and structure.
02 / REPRESENTATION
Representation
The same canonical record is rendered below in three issued representations: Issued Document (PDF/A-2b), HTML, and Structured Text.
Format: PDF/A-2b · Distributed to authorized recipients.
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="schema-version" content="3.2">
<title>MT-2026-02-18-V1</title>
</head>
<body>
<header class="matilon-research">
<h1>MATILON RESEARCH</h1>
</header>
<section data-section="record-control">
<h2>RECORD CONTROL</h2>
<dl>
<dt>TYPE</dt><dd>INTELLIGENCE RECORD</dd>
<dt>RECORD ID</dt><dd>MT-2026-02-18-V1</dd>
<dt>PRECEDING RECORD</dt><dd>MT-2026-02-11-V1</dd>
<dt>RECORD SIGNATURE</dt><dd>7A2E9C4F-3B81-4D56-A9E3-2F7C8B1D5E04</dd>
<dt>VERSION</dt><dd>1.0</dd>
<dt>STATUS</dt><dd>FINALIZED</dd>
<dt>ISSUED</dt><dd>2026-02-18</dd>
<dt>RECORD MODE</dt><dd>APPEND-ONLY</dd>
<dt>RETENTION PERIOD</dt><dd>PERMANENT</dd>
<dt>SCHEMA VERSION</dt><dd>3.2</dd>
<dt>ACCESS CLASSIFICATION</dt><dd>EXECUTIVE</dd>
</dl>
</section>
<section data-section="confidentiality-notice">
<h2>CONFIDENTIALITY NOTICE</h2>
<p>This document and all associated data, content, and information ("Material") are proprietary to Matilon and are provided solely for authorized use. The Material may contain confidential, sensitive, or privileged information. Unauthorized access, use, disclosure, distribution, reproduction, or retention of any portion of the Material is strictly prohibited. Recipients shall protect the Material with reasonable care and use it solely for its intended purpose. The Material may not be shared, disclosed, or made accessible, in whole or in part, outside the recipient's organization without prior written authorization from Matilon. Recipients shall ensure that any permitted access to the Material is limited to authorized personnel under equivalent confidentiality obligations.</p>
</section>
<section data-section="intelligence-record">
<h2>INTELLIGENCE RECORD</h2>
<article data-entry="MT-2026-02-18-V1-E1">
<dl class="entry-meta">
<dt>ENTRY ID</dt><dd>MT-2026-02-18-V1-E1</dd>
<dt>INGESTION ID</dt><dd>3C9F1A47-5D8B-4E62-B1F4-8A2E6C5D3B19</dd>
<dt>ENTITY</dt><dd>FUJIFILM BIOTECHNOLOGIES</dd>
<dt>SUBJECT</dt><dd>TEESSIDE SINGLE-USE BIOREACTOR CAPACITY EXPANSION</dd>
<dt>SUBJECT CLASS</dt><dd>EXPANSION</dd>
<dt>DOMAIN</dt><dd>BIOMANUFACTURING CAPACITY</dd>
<dt>GEOGRAPHY</dt><dd>UNITED KINGDOM</dd>
<dt>FUNCTIONAL DOMAIN</dt><dd>PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS</dd>
</dl>
<div class="entry-body">
<h3>DEFINITION:</h3>
<p>FUJIFILM Biotechnologies opened a £400 million Teesside expansion, adding 2,000 L and 5,000 L single-use bioreactors alongside new process development laboratories.</p>
<h3>STRUCTURE:</h3>
<p>End-to-end workflows now run from customer-supplied DNA through cell line development to 5,000 L scale-up, reducing external handoffs during tech transfer.</p>
<h3>EFFECT:</h3>
<p>Raises the value of standardized process definitions, facility layouts, and shared digital templates as Teesside aligns with FUJIFILM's Toyama facility.</p>
</div>
</article>
<article data-entry="MT-2026-02-18-V1-E2">
<dl class="entry-meta">
<dt>ENTRY ID</dt><dd>MT-2026-02-18-V1-E2</dd>
<dt>INGESTION ID</dt><dd>8E4A2F91-6C3D-4B57-9A2E-1F5C8D7B4A63</dd>
<dt>ENTITY</dt><dd>MADE SCIENTIFIC; STREAMLINE BIO</dd>
<dt>SUBJECT</dt><dd>ROBOTIC CAR-T PLATFORM INTEGRATION AND VALIDATION</dd>
<dt>SUBJECT CLASS</dt><dd>INTEGRATION</dd>
<dt>DOMAIN</dt><dd>AUTOMATED CELL THERAPY SYSTEMS</dd>
<dt>GEOGRAPHY</dt><dd>UNITED STATES</dd>
<dt>FUNCTIONAL DOMAIN</dt><dd>ADVANCED THERAPIES MANUFACTURING; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS</dd>
</dl>
<div class="entry-body">
<h3>DEFINITION:</h3>
<p>Made Scientific joined Streamline Bio's early adopter program to integrate and validate Streamline's AI-driven robotic platform within Made's GMP operations.</p>
<h3>STRUCTURE:</h3>
<p>New unit operations, enhanced in-process analytics, and expanded data capture characterize autonomous CAR-T steps across cycle time, robustness, and scalability.</p>
<h3>EFFECT:</h3>
<p>Concentrates early validation and integration patterns at a single CDMO site, accelerating later rollout while deepening dependence on site-specific procedures.</p>
</div>
</article>
<article data-entry="MT-2026-02-18-V1-E3">
<dl class="entry-meta">
<dt>ENTRY ID</dt><dd>MT-2026-02-18-V1-E3</dd>
<dt>INGESTION ID</dt><dd>1D6B3E84-7F92-4A58-B3C1-5E2F9A8D6C47</dd>
<dt>ENTITY</dt><dd>OXFORD BIOMEDICA; BRISTOL MYERS SQUIBB</dd>
<dt>SUBJECT</dt><dd>LENTIVIRAL VECTOR COMMERCIAL SUPPLY AGREEMENT</dd>
<dt>SUBJECT CLASS</dt><dd>SUPPLY</dd>
<dt>DOMAIN</dt><dd>VIRAL VECTOR MANUFACTURING</dd>
<dt>GEOGRAPHY</dt><dd>UNITED KINGDOM; UNITED STATES</dd>
<dt>FUNCTIONAL DOMAIN</dt><dd>PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS</dd>
</dl>
<div class="entry-body">
<h3>DEFINITION:</h3>
<p>Oxford Biomedica signed a five-year commercial supply agreement, with an extension option, to manufacture lentiviral vectors for Bristol Myers Squibb CAR-T programs.</p>
<h3>STRUCTURE:</h3>
<p>Commercial manufacturing is expected to begin in 2026, subject to regulatory approvals, across Oxford, United Kingdom and Durham, North Carolina sites.</p>
<h3>EFFECT:</h3>
<p>Requires aligned control strategies, harmonized release specifications, and quality data exchange across both sites to hold consistent commercial output through the supply term.</p>
</div>
</article>
<article data-entry="MT-2026-02-18-V1-E4">
<dl class="entry-meta">
<dt>ENTRY ID</dt><dd>MT-2026-02-18-V1-E4</dd>
<dt>INGESTION ID</dt><dd>5F2C9A18-3E7B-4D64-A8F2-6B1E5C9D3A72</dd>
<dt>ENTITY</dt><dd>GEMINIBIO; TOLEMY BIO</dd>
<dt>SUBJECT</dt><dd>AI-DRIVEN CUSTOM MEDIA SUPPLEMENT SERVICE INTRODUCTION</dd>
<dt>SUBJECT CLASS</dt><dd>DEPLOYMENT</dd>
<dt>DOMAIN</dt><dd>BIOPROCESS MEDIA DESIGN</dd>
<dt>GEOGRAPHY</dt><dd>UNITED STATES</dd>
<dt>FUNCTIONAL DOMAIN</dt><dd>PROCESS DEVELOPMENT AND MSAT; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS</dd>
</dl>
<div class="entry-body">
<h3>DEFINITION:</h3>
<p>GeminiBio and Tolemy Bio introduced aiMOS, a service applying AI/ML and multi-omics to design custom media supplements for cell therapy processes and manufacture them to cGMP standards.</p>
<h3>STRUCTURE:</h3>
<p>AI/ML modeling over multi-omics data designs custom supplements for tighter critical quality attributes and lower batch variability, reducing iterative media tuning cycles.</p>
<h3>EFFECT:</h3>
<p>Adds dataset governance and supplement change-control requirements, with model outputs needing controlled mapping into MES, CMC documentation, and release records before formulations reach GMP production.</p>
</div>
</article>
<article data-entry="MT-2026-02-18-V1-E5">
<dl class="entry-meta">
<dt>ENTRY ID</dt><dd>MT-2026-02-18-V1-E5</dd>
<dt>INGESTION ID</dt><dd>9A7E4C2F-8B5D-4163-9E2A-3F8C1B6D5E94</dd>
<dt>ENTITY</dt><dd>NUCLEUS BIOLOGICS</dd>
<dt>SUBJECT</dt><dd>KRAKATOA K500 POINT-OF-USE MEDIA POD LAUNCH</dd>
<dt>SUBJECT CLASS</dt><dd>DEPLOYMENT</dd>
<dt>DOMAIN</dt><dd>POINT-OF-USE MEDIA SYSTEMS</dd>
<dt>GEOGRAPHY</dt><dd>UNITED STATES</dd>
<dt>FUNCTIONAL DOMAIN</dt><dd>AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS; ADVANCED THERAPIES MANUFACTURING</dd>
</dl>
<div class="entry-body">
<h3>DEFINITION:</h3>
<p>Nucleus Biologics launched Krakatoa K500, a pod-based single-use system producing 35–500 L of sterile media and buffers at the point of use.</p>
<h3>STRUCTURE:</h3>
<p>QR-code execution, inline pH and conductivity monitoring, and automated digital batch records reduce centralized liquid prep and cold storage while preserving traceability.</p>
<h3>EFFECT:</h3>
<p>Shifts media and buffer preparation to the point of use, reopening qualification boundaries, cleanroom layouts, and validation scope as liquid prep moves beside the bioreactor.</p>
</div>
</article>
</section>
<section data-section="disclaimer-of-liability">
<h2>DISCLAIMER OF LIABILITY</h2>
<p>This document and all associated data, content, analyses, and information ("Material") are provided by Matilon for informational and internal decision-support purposes only. The Material is provided without representation as to its completeness or sufficiency; accordingly, Matilon makes no representations or warranties, express or implied, as to the accuracy, completeness, timeliness, reliability, or fitness for any particular purpose of the Material. The Material does not constitute legal, financial, technical, or strategic advice, and shall not be relied upon as the sole basis for any decision, action, or omission. Any use of or reliance on the Material is undertaken at the recipient's sole risk and discretion. To the fullest extent permitted by applicable law, Matilon disclaims all liability for any direct, indirect, incidental, consequential, or special damages arising out of or in connection with the use of, or inability to use, the Material, including any errors or omissions therein. Matilon assumes no obligation to update, correct, revise, or supplement the Material and reserves all rights with respect to its use and distribution.</p>
</section>
<footer>
<p>MT-2026-02-18-V1 | VERSION 1.0 | 2026-02-18</p>
<p>© MATILON. ALL RIGHTS RESERVED.</p>
</footer>
</body>
</html>MATILON RESEARCH
RECORD CONTROL
TYPE: INTELLIGENCE RECORD
RECORD ID: MT-2026-02-18-V1
PRECEDING RECORD: MT-2026-02-11-V1
RECORD SIGNATURE: 7A2E9C4F-3B81-4D56-A9E3-2F7C8B1D5E04
VERSION: 1.0
STATUS: FINALIZED
ISSUED: 2026-02-18
RECORD MODE: APPEND-ONLY
RETENTION PERIOD: PERMANENT
SCHEMA VERSION: 3.2
ACCESS CLASSIFICATION: EXECUTIVE
CONFIDENTIALITY NOTICE
This document and all associated data, content, and information ("Material") are proprietary to Matilon and are provided solely for authorized use. The Material may contain confidential, sensitive, or privileged information. Unauthorized access, use, disclosure, distribution, reproduction, or retention of any portion of the Material is strictly prohibited. Recipients shall protect the Material with reasonable care and use it solely for its intended purpose. The Material may not be shared, disclosed, or made accessible, in whole or in part, outside the recipient's organization without prior written authorization from Matilon. Recipients shall ensure that any permitted access to the Material is limited to authorized personnel under equivalent confidentiality obligations.
INTELLIGENCE RECORD
ENTRY ID: MT-2026-02-18-V1-E1
INGESTION ID: 3C9F1A47-5D8B-4E62-B1F4-8A2E6C5D3B19
ENTITY: FUJIFILM BIOTECHNOLOGIES
SUBJECT: TEESSIDE SINGLE-USE BIOREACTOR CAPACITY EXPANSION
SUBJECT CLASS: EXPANSION
DOMAIN: BIOMANUFACTURING CAPACITY
GEOGRAPHY: UNITED KINGDOM
FUNCTIONAL DOMAIN: PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS
DEFINITION:
FUJIFILM Biotechnologies opened a £400 million Teesside expansion, adding 2,000 L and 5,000 L single-use bioreactors alongside new process development laboratories.
STRUCTURE:
End-to-end workflows now run from customer-supplied DNA through cell line development to 5,000 L scale-up, reducing external handoffs during tech transfer.
EFFECT:
Raises the value of standardized process definitions, facility layouts, and shared digital templates as Teesside aligns with FUJIFILM's Toyama facility.
ENTRY ID: MT-2026-02-18-V1-E2
INGESTION ID: 8E4A2F91-6C3D-4B57-9A2E-1F5C8D7B4A63
ENTITY: MADE SCIENTIFIC; STREAMLINE BIO
SUBJECT: ROBOTIC CAR-T PLATFORM INTEGRATION AND VALIDATION
SUBJECT CLASS: INTEGRATION
DOMAIN: AUTOMATED CELL THERAPY SYSTEMS
GEOGRAPHY: UNITED STATES
FUNCTIONAL DOMAIN: ADVANCED THERAPIES MANUFACTURING; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS
DEFINITION:
Made Scientific joined Streamline Bio's early adopter program to integrate and validate Streamline's AI-driven robotic platform within Made's GMP operations.
STRUCTURE:
New unit operations, enhanced in-process analytics, and expanded data capture characterize autonomous CAR-T steps across cycle time, robustness, and scalability.
EFFECT:
Concentrates early validation and integration patterns at a single CDMO site, accelerating later rollout while deepening dependence on site-specific procedures.
ENTRY ID: MT-2026-02-18-V1-E3
INGESTION ID: 1D6B3E84-7F92-4A58-B3C1-5E2F9A8D6C47
ENTITY: OXFORD BIOMEDICA; BRISTOL MYERS SQUIBB
SUBJECT: LENTIVIRAL VECTOR COMMERCIAL SUPPLY AGREEMENT
SUBJECT CLASS: SUPPLY
DOMAIN: VIRAL VECTOR MANUFACTURING
GEOGRAPHY: UNITED KINGDOM; UNITED STATES
FUNCTIONAL DOMAIN: PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS
DEFINITION:
Oxford Biomedica signed a five-year commercial supply agreement, with an extension option, to manufacture lentiviral vectors for Bristol Myers Squibb CAR-T programs.
STRUCTURE:
Commercial manufacturing is expected to begin in 2026, subject to regulatory approvals, across Oxford, United Kingdom and Durham, North Carolina sites.
EFFECT:
Requires aligned control strategies, harmonized release specifications, and quality data exchange across both sites to hold consistent commercial output through the supply term.
ENTRY ID: MT-2026-02-18-V1-E4
INGESTION ID: 5F2C9A18-3E7B-4D64-A8F2-6B1E5C9D3A72
ENTITY: GEMINIBIO; TOLEMY BIO
SUBJECT: AI-DRIVEN CUSTOM MEDIA SUPPLEMENT SERVICE INTRODUCTION
SUBJECT CLASS: DEPLOYMENT
DOMAIN: BIOPROCESS MEDIA DESIGN
GEOGRAPHY: UNITED STATES
FUNCTIONAL DOMAIN: PROCESS DEVELOPMENT AND MSAT; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS
DEFINITION:
GeminiBio and Tolemy Bio introduced aiMOS, a service applying AI/ML and multi-omics to design custom media supplements for cell therapy processes and manufacture them to cGMP standards.
STRUCTURE:
AI/ML modeling over multi-omics data designs custom supplements for tighter critical quality attributes and lower batch variability, reducing iterative media tuning cycles.
EFFECT:
Adds dataset governance and supplement change-control requirements, with model outputs needing controlled mapping into MES, CMC documentation, and release records before formulations reach GMP production.
ENTRY ID: MT-2026-02-18-V1-E5
INGESTION ID: 9A7E4C2F-8B5D-4163-9E2A-3F8C1B6D5E94
ENTITY: NUCLEUS BIOLOGICS
SUBJECT: KRAKATOA K500 POINT-OF-USE MEDIA POD LAUNCH
SUBJECT CLASS: DEPLOYMENT
DOMAIN: POINT-OF-USE MEDIA SYSTEMS
GEOGRAPHY: UNITED STATES
FUNCTIONAL DOMAIN: AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS; ADVANCED THERAPIES MANUFACTURING
DEFINITION:
Nucleus Biologics launched Krakatoa K500, a pod-based single-use system producing 35–500 L of sterile media and buffers at the point of use.
STRUCTURE:
QR-code execution, inline pH and conductivity monitoring, and automated digital batch records reduce centralized liquid prep and cold storage while preserving traceability.
EFFECT:
Shifts media and buffer preparation to the point of use, reopening qualification boundaries, cleanroom layouts, and validation scope as liquid prep moves beside the bioreactor.
DISCLAIMER OF LIABILITY
This document and all associated data, content, analyses, and information ("Material") are provided by Matilon for informational and internal decision-support purposes only. The Material is provided without representation as to its completeness or sufficiency; accordingly, Matilon makes no representations or warranties, express or implied, as to the accuracy, completeness, timeliness, reliability, or fitness for any particular purpose of the Material. The Material does not constitute legal, financial, technical, or strategic advice, and shall not be relied upon as the sole basis for any decision, action, or omission. Any use of or reliance on the Material is undertaken at the recipient's sole risk and discretion. To the fullest extent permitted by applicable law, Matilon disclaims all liability for any direct, indirect, incidental, consequential, or special damages arising out of or in connection with the use of, or inability to use, the Material, including any errors or omissions therein. Matilon assumes no obligation to update, correct, revise, or supplement the Material and reserves all rights with respect to its use and distribution.
MT-2026-02-18-V1 | VERSION 1.0 | 2026-02-18
© MATILON. ALL RIGHTS RESERVED.03 / CROSS-REFERENCES
Cross-References
Matilon Research Specimen · Schema v3.2